Back

Efficacy and safety of dapagliflozin according to baseline blood pressure - Observations from DECLARE-TIMI 58 Trial

29 August 2020 (08:30 - 08:36)
Organised by:
Congress Presentation Part of: Blockbusters from the Young in Factors and Prevention / Preventive Cardiology Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Remo Holanda De Mendonca Furtado

Brazilian Clinical Research Institute (BCRI), Sao Paulo (Brazil)

1 More presentation in this session

Presentation thumbnail
Impact of physical activity on all-cause mortality in European patients with atrial fibrillation: a report from the ESC-EHRA EORP AF General Long-Term Registry
Doctor M. Vitolo (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Blockbusters from the Young in Factors and Prevention / Preventive Cardiology

The Event

Event poster

ESC Congress 2020

29 August 2020 08:30 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources